Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set ...

"Bristol Myers Squibb is advancing novel approaches to address high unmet needs in cancer and at this year’s ASCO meeting, we are highlighting data across a range of assets, including our ...

will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. The abstract of the study has been released today. To ...

Alligator's participation at ASCO reflects its commitment to scientific exchange and business development. The meeting provides an important platform to highlight mitazalimab's potential and ...

Immix Biopharma (IMMX) today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety.

At ASCO, AZ reported the full data from its DUO-O study of PD-L1 inhibitor Imfinzi (durvalumab) as a combination regimen with its PARP inhibitor Lynparza (olaparib) given on top of standard first ...

The oncology community’s biggest gathering returns to Chicago from May 30 to June 3, and all signs suggest the 2025 ASCO Annual Meeting will be a watershed moment. This year’s theme is Driving ...

2025 ASCO Annual Meeting Search Within This Issue Quick Search Enter words / phrases / DOI / ISBN / keywords / authors / etc Search Next INVITED ARTICLES Free Access INVITED ARTICLES May 19, 2025 ...

Please submit gameplay bugs for the Dota team to look at here. We'd like to use the "thumbs up" reaction as an upvote to track priority from the community, so to "+1" an issue please add a thumbs up ...